

# Bortezomib: Suggested Dose Modifications

## Dose Modification for the Management of Peripheral Neuropathy

<b>Severity of Peripheral Neuropathy Signs/Symptoms</b>	<b>Modification of Dose and Regimen</b>
Grade 1 (paresthesia, weakness, and/or loss of reflexes without pain or loss of function)	No action
Grade 1 with pain or grade 2 (interfering with function but not with activities of daily living)	Reduce bortezomib to 1.0 mg/m <sup>2</sup>
Grade 2 with pain or grade 3 (interfering with activities of daily living)	Withhold bortezomib therapy until toxicity resolves. When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m <sup>2</sup> and change treatment schedule to once per week
Grade 4 (sensory neuropathy that is disabling, or motor neuropathy that is life-threatening or leads to paralysis)	Discontinue bortezomib

**Symptoms may improve or return to baseline in some patients on discontinuation of bortezomib**

## Dose Modification Recommendations for Adverse Events, Excluding Peripheral Neuropathy

- At the onset of grade 3 nonhematologic toxicities, therapy with bortezomib should be held
- At the onset of grade 4 hematologic toxicities, therapy with bortezomib should be held
- Once toxicity has resolved, bortezomib may be reinitiated at a 25% reduced dose
  - 1.3 mg/m<sup>2</sup> per dose reduced to 1.0 mg/m<sup>2</sup> per dose
  - 1.0 mg/m<sup>2</sup> per dose reduced to 0.7 mg/m<sup>2</sup> per dose
- Decreased neuropathy, nausea, and diarrhea seen when dose is decreased